查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951173

合成生物學市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、產品、最終用戶、地區及競爭格局分類，2021-2031年）

Synthetic Biology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Product, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球合成生物學市場預計將從 2025 年的 128.1 億美元成長到 2031 年的 180.6 億美元，複合年成長率為 5.89%。

該領域專注於設計生物建構模組，以改造現有生物系統，使其具備新的功能或帶來實際效益。市場成長的主要驅動力是DNA定序和合成成本的大幅降低，以及工業界對可再生生物基替代品（例如傳統化學品和材料）日益成長的需求。這些結構性促進因素滿足了供應鏈韌性和環境永續性的關鍵需求，使該領域區別於瞬息萬變的技術趨勢，並為長期發展奠定了堅實的基礎。

市場概覽
預測期 2027-2031
市場規模：2025年 128.1億美元
市場規模：2031年 180.6億美元
複合年成長率：2026-2031年 5.89%
成長最快的細分市場 PCR技術
最大的市場 北美洲

然而，生物製造在擴充性仍面臨許多挑戰，從實驗室環境到商業化生產，存在著複雜的技術和經濟難題。儘管有這些限制，投資活動依然強勁，凸顯了相關人員對該領域商業性潛力的堅定信心。根據SynBioBeta的數據，到2024年，全球合成生物學領域的創投將達到122億美元，這標誌著金融信心的恢復以及推動這些技術走向市場成熟的持續努力。

市場促進因素

人工智慧 (AI) 和機器學習的融合正成為推動全球合成生物學市場變革的驅動力，從根本上改變了生物工程的速度和精確度。這些計算工具能夠對複雜的生物系統進行預測建模，使研究人員無需進行大量的試驗實驗即可設計新型蛋白質及其相互作用。這種技術融合顯著加速了藥物發現和材料科學領域的應用，使以往難以高效分析的生物數據得以有效解讀。例如，GoogleDeepMind在2024年5月的一篇部落格報導中報告稱，其AlphaFold 3模型在蛋白質交互作用預測的準確率方面比以往的方法至少提高了50%。這項改進轉化為更低的開發成本和更短的開發週期，從而促進了更廣泛的工業應用。

此外，政府撥款和私人投資的增加正在推動市場成長，為實驗室階段的創新成果實現商業化規模提供了所需的資金。公共部門的各項措施日益重視生物工程，以增強國家供應鏈的韌性和生物安全，而私人資本則瞄準那些展現出盈利和規模化潛力的公司。例如，英國研究與創新署（UKRI）於2024年11月宣布投資580萬英鎊，用於支持種子計畫和概念驗證計劃，以實現生物工程領域突破性成果的商業化。這項資金投入勢頭凸顯了全球對合成DNA和基因組工具日益成長的需求，推動了該產業的擴張。 Twist Biosciences公司就是一個例證，該公司在2024會計年度創下了3.13億美元的年營收紀錄。

市場挑戰

生物製造的可擴展性是全球合成生物學市場擴張面臨的最大結構性障礙。從實驗室規模的實驗到工業級商業化的過渡帶來了複雜的技術挑戰，因為生物系統在大規模生產中往往會表現出不穩定的行為和產量下降。這種技術上的不可預測性使得企業難以實現與現有石化企業競爭所需的單位成本優勢。此外，全球供應鏈缺乏合適的配套基礎設施，迫使創新者依賴老舊的製藥設施，而這些設施並不適合工業化學品和食品配料所需的低利潤成本結構。

基礎設施短缺導致市場滿足商業性需求的能力出現顯著差距。根據 SynBioBeta 預測，到 2024 年，該產業將面臨嚴重的產能短缺，全球發酵產能需求將比現有產能高出約 10 到 100 倍，具體倍數取決於生產規模。這種頻寬的短缺直接阻礙了合成生物學技術的市場應用，導致產品上市嚴重延遲，並限制了該行業的產生收入能力。

市場趨勢

酶促DNA合成技術的興起正在改變市場格局，高效的酶促生產過程正在取代傳統的化學亞磷醯胺法。這項轉變滿足了代謝工程和基因組學研究對長而複雜的DNA序列的迫切需求，同時避免了使用有害的有機溶劑。該技術的快速成熟正吸引大量資金流入能夠提供商業規模解決方案的公司，從而推動了傳統化學工藝的淘汰。例如，安莎生物技術公司（Ansa Biotechnology）在2025年10月的新聞稿中宣布，已完成超額認購的5,440萬美元B輪資金籌措，用於擴展其專有的酵素合成平台，凸顯了該產業向永續生產標準的轉變。

此外，合成生物學在細胞農業領域的商業化正超越研究階段，越來越多的公司正在籌集大量資金籌措以擴大營運規模並進入全球食品市場。這一趨勢反映出，企業正著力實現與傳統肉類生產相當的單位經濟效益，並透過與專業投資銀行合作來加速市場准入。主要企業從試點設施轉向工業化生產，以滿足消費者對永續蛋白質來源的需求，這清楚地展現了這一進展。 2025年11月，Meatable宣布與一家投資銀行合作完成3,000萬歐元的資金籌措，鞏固了其作為全球培養肉領導者的地位。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球合成生物學市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按技術（次世代定序技術、PCR技術、基因組編輯技術、生物製程技術、其他技術）
    • 依產品（寡核苷酸/寡核苷酸叢集和合成DNA、酵素、克隆技術試劑盒、異源核酸、底盤生物體）
    • 依最終用戶（生技/製藥公司、學術/政府研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美合成生物學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲合成生物學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區合成生物學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲合成生物學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲合成生物學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球合成生物學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bota Biosciences Inc.
  • Codexis, Inc.
  • Enbiotix, Inc.
  • Illumina, Inc.
  • Merck Kgaa（Sigma-Aldrich Co. Llc）
  • Pareto Bio, Inc.
  • Scarab Genomics, Llc
  • Synthego Corporation
  • Synthetic Genomics Inc.
  • Thermo Fisher Scientific, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24009

The Global Synthetic Biology Market is projected to expand from USD 12.81 Billion in 2025 to USD 18.06 Billion by 2031, reflecting a compound annual growth rate of 5.89%. This field focuses on engineering biological components to develop new functionalities or modify existing biological systems for practical utility. The market's growth is primarily underpinned by dramatic reductions in DNA sequencing and synthesis costs, alongside rising industrial demand for renewable, bio-based substitutes for traditional chemicals and materials. These structural drivers establish a firm foundation for long-term progress, differentiating the sector from fleeting technological trends by addressing critical needs in supply chain resilience and environmental sustainability.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.81 Billion
Market Size 2031USD 18.06 Billion
CAGR 2026-20315.89%
Fastest Growing SegmentPCR Technology
Largest MarketNorth America

However, the industry faces a significant obstacle regarding the scalability of biomanufacturing, as moving from laboratory settings to commercial production presents intricate technical and economic difficulties. Despite these constraints, investment activity remains robust, underscoring strong stakeholder confidence in the sector's commercial possibilities. Data from SynBioBeta indicates that in 2024, global venture capital investment in synthetic biology reached $12.2 billion, signaling renewed financial confidence and an ongoing dedication to advancing these technologies toward market maturity.

Market Driver

The integration of artificial intelligence and machine learning acts as a transformative driver for the global synthetic biology market, fundamentally changing the pace and precision of biological engineering. These computational tools facilitate the predictive modeling of intricate biological systems, enabling researchers to design new proteins and interactions without the need for extensive trial-and-error experimentation. This technological convergence notably accelerates applications in drug discovery and material science by interpreting biological data previously considered too complex for efficient analysis. For instance, Google DeepMind reported in a May 2024 blog post that its AlphaFold 3 model achieved at least a 50% increase in prediction accuracy for protein interactions compared to earlier methods, a level of precision that lowers development costs and timelines, thus promoting wider industrial adoption.

Furthermore, rising government funding and private investment are accelerating market growth by supplying the capital needed to scale innovations from the laboratory to commercial viability. Public sector initiatives are increasingly prioritizing engineering biology to bolster national supply chain resilience and biosecurity, while private capital targets companies demonstrating revenue potential and operational scalability. As an example, UK Research and Innovation announced a £5.8 million investment in November 2024 to support seed and proof-of-concept projects for commercializing engineering biology breakthroughs. This financial momentum drives the sector's expansion, as demonstrated by Twist Bioscience, which reported a record fiscal year revenue of $313.0 million in 2024, emphasizing the growing global demand for synthetic DNA and genomic tools.

Market Challenge

Scalability in biomanufacturing constitutes the most significant structural barrier to the expansion of the Global Synthetic Biology Market. The transition from laboratory-scale experiments to industrial-grade commercialization creates complex technical hurdles, as biological systems often demonstrate unstable behaviors and diminished yields when scaled up to larger volumes. This technical unpredictability makes it difficult for companies to attain the unit economics required to compete with established petrochemical products. Additionally, the global supply chain faces a shortage of fit-for-purpose infrastructure, compelling innovators to depend on aging pharmaceutical facilities that are ill-suited for the low-margin cost structures necessary for industrial chemicals or food ingredients.

This infrastructure deficit has resulted in a measurable gap in the market's capacity to satisfy commercial requirements. According to SynBioBeta, the industry faced a critical shortfall in 2024, with global demand for fermentation capacity outstripping available supply by approximately 10 to 100 times, depending on the scale of production. This scarcity of manufacturing bandwidth causes significant delays in product launches and limits the industry's revenue-generating capability, thereby directly impeding the wider market adoption of synthetic biology technologies.

Market Trends

The shift toward Enzymatic DNA Synthesis Technologies is reshaping the market by replacing traditional chemical phosphoramidite methods with efficient, enzyme-based manufacturing. This transition meets the critical demand for longer, more complex DNA sequences essential for metabolic engineering and genomic research while simultaneously removing the need for hazardous organic solvents. The rapid maturation of this technology is driving significant capital allocation toward companies capable of delivering commercial-scale solutions, validating the industry's move away from legacy chemical processes. For instance, Ansa Biotechnologies announced in an October 2025 press release that it secured an oversubscribed $54.4 million Series B funding round to expand its proprietary enzymatic synthesis platform, underscoring the sector's pivot to this sustainable production standard.

Additionally, the commercialization of synthetic biology within cellular agriculture is advancing beyond the research phase, with companies securing substantial funding to scale operations and penetrate global food markets. This trend reflects a strategic focus on establishing unit economics that rival conventional meat production, supported by specialized investment banking partnerships designed to expedite market entry. This progression is evident as leading players transition from pilot facilities to industrial-grade output to meet consumer demand for sustainable protein sources. In November 2025, Meatable announced a partnership with an investment bank to place €30 million of capital, aiming to establish the firm as a global leader in the cultivated meat sector.

Key Market Players

  • Bota Biosciences Inc.
  • Codexis, Inc.
  • Enbiotix, Inc.
  • Illumina, Inc.
  • Merck Kgaa (Sigma-Aldrich Co. Llc)
  • Pareto Bio, Inc.
  • Scarab Genomics, Llc
  • Synthego Corporation
  • Synthetic Genomics Inc.
  • Thermo Fisher Scientific, Inc.

Report Scope

In this report, the Global Synthetic Biology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Biology Market, By Technology

  • NGS Technology
  • PCR Technology
  • Genome Editing Technology
  • Bioprocessing Technology
  • Other Technologies

Synthetic Biology Market, By Product

  • Oligonucleotide/Oligo Pools and Synthetic DNA
  • Enzymes
  • Cloning Technologies Kits
  • Xeno-Nucleic Acids
  • Chassis Organism

Synthetic Biology Market, By End user

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Others

Synthetic Biology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Biology Market.

Available Customizations:

Global Synthetic Biology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Synthetic Biology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (NGS Technology, PCR Technology, Genome Editing Technology, Bioprocessing Technology, Other Technologies)
    • 5.2.2. By Product (Oligonucleotide/Oligo Pools and Synthetic DNA, Enzymes, Cloning Technologies Kits, Xeno-Nucleic Acids, Chassis Organism)
    • 5.2.3. By End user (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Synthetic Biology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Product
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Synthetic Biology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Synthetic Biology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Synthetic Biology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By End user

7. Europe Synthetic Biology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Product
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Synthetic Biology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By End user
    • 7.3.2. France Synthetic Biology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Synthetic Biology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Synthetic Biology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Synthetic Biology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By End user

8. Asia Pacific Synthetic Biology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Synthetic Biology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By End user
    • 8.3.2. India Synthetic Biology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Synthetic Biology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Synthetic Biology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Synthetic Biology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By End user

9. Middle East & Africa Synthetic Biology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Product
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Synthetic Biology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Synthetic Biology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Synthetic Biology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By End user

10. South America Synthetic Biology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Product
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Synthetic Biology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Synthetic Biology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Synthetic Biology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Synthetic Biology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bota Biosciences Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Codexis, Inc.
  • 15.3. Enbiotix, Inc.
  • 15.4. Illumina, Inc.
  • 15.5. Merck Kgaa (Sigma-Aldrich Co. Llc)
  • 15.6. Pareto Bio, Inc.
  • 15.7. Scarab Genomics, Llc
  • 15.8. Synthego Corporation
  • 15.9. Synthetic Genomics Inc.
  • 15.10. Thermo Fisher Scientific, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer